George W. Sledge

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Long Road Home: The Continuing Journey of Metastatic Disease

  JCO Oncology Practice · 2026-06-25

• Supplementary Table 4 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Supplementary Table 1 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Data from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Supplementary Figures 1-8 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

  2026-06-17

• Social deprivation index (SDI) as a predictor of racial and ethnic disparity in a large real world cancer database.

  Journal of Clinical Oncology · 2026-05-28

• Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases

  Clinical Cancer Research · 2026-04-30

• Abstract 6647: MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance.

  Cancer Research · 2026-04-03

• Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16

• Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

  2026-03-16